What Pharma Research Bio does

PharmaResearch Bio Co., Ltd. (주식회사 파마리서치바이오) is a Korean biopharmaceutical company founded in 2009 (originally as BIOCND Co., Ltd., renamed in 2018) that specializes exclusively in botulinum toxin products for aesthetic and therapeutic applications. The company operates as a subsidiary of PharmaResearch (파마리서치), is listed on the KONEX market (since 2015), and is headquartered with a GMP-certified manufacturing facility in Gangneung, Gangwon-do, while R&D activities are conducted from a Seongnam, Gyeonggi-do laboratory. As of 2025 the company has 77 regular employees. PharmaResearch Bio's product portfolio centers on two commercialized SKUs: Re N Tox Inj 100 units for the domestic Korean market (MFDS-approved February 2024, commercial launch April 2025) and Re N Tox in 100- and 200-unit formulations for export markets. The company's proprietary technology stack includes botulinum toxin protein purification achieving 99.97% purity for the 900kDa complex, purification of the 150kDa pure neurotoxin, and a Polynucleotide (PN) bio-persistence enhancement that extends muscle relaxation duration up to 2.3x. A pipeline of four next-generation candidates (BCD200 with Phase 3 completed in 2021, PRB004 liquid-type, PRB002 150kDa, PRB005 next-generation) and a PN Calcium Filler composition expand the franchise beyond the lead toxin.

The business model is B2B prescription pharmaceutical distribution through enterprise field sales targeting medical aesthetic clinics, dermatology clinics, and hospitals. Domestically, products move through prescription channels requiring medical professional authorization; internationally, distribution targets Thailand (where TFDA approval was secured in August 2025), Southeast Asia, and prospective European markets. A second EU-GMP compliant manufacturing facility is under construction at the Gangneung Science Industrial Complex (7,905 sqm, completion targeted 2026, planned 6 million vials per year capacity), backed by a 193 billion KRW investment agreement with Gangneung City and Gangwon Province. The company has achieved the 10 Million Dollar Export Tower award in 2023, reflecting over 70% average annual revenue growth since the 2019 export initiation. The company is led by co-CEOs Baek Seung-gul and Dr. Won Ji-yeob (formerly of Roche, Johnson & Johnson, and Allergan).

Name

Pharma Research Bio

Legal name

주식회사 파마리서치바이오 (PharmaResearch Bio Co., Ltd.)

Website

https://pr-bio.co.kr

Company type

Private

Founded year

2009

Operating status

Operating

Short description

PharmaResearch Bio is a Korean biopharmaceutical subsidiary of PharmaResearch that develops, manufactures, and sells prescription botulinum toxin products (Re N Tox) for medical aesthetic clinics, dermatology clinics, and hospitals in domestic and export markets.

Ownership category

akta.pro rank

Product category

Aesthetic Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (4242)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Raw Materials & Critical Reagents Supply Services (media, resins, single-use) (HLAAAKAI)

akta.pro secondary industry

Specialty Pharmaceutical Distributors (HLAIAJAB)

Keywords

• Botulinum toxin products
• Aesthetic pharmaceuticals
• Biopharmaceutical manufacturing
• Prescription injectables
• Medical aesthetics drugs

Headquarters

HQ city

Gangneung

HQ country

South Korea

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Infrastructure, Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

1. Botulinum Toxin Product Sales: Sale of botulinum toxin pharmaceutical products including Re N Tox (domestic use) and Re N ToxS (export use) in 100-unit and 200-unit formulations.
2. Pharmaceutical Product Licensing: Revenue from obtaining product approvals and licensing botulinum toxin products for global markets.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

PharmaResearch Bio manufactures and sells prescription Clostridium botulinum toxin Type A injectable products (Re N Tox Inj 100 units for domestic Korean use and Re N Tox 100/200 units for export) for the temporary improvement of moderate to severe glabellar lines in adults aged 19–65. The company produces these sterile injectables at its GMP-certified Gangneung facility, supported by a vertically integrated pipeline spanning botulinum toxin cultivation, purification (99.97% purity), and proprietary PN-enhanced formulation, and is expanding export distribution to markets including Thailand and broader Southeast Asia.

Product overview

PharmaResearch Bio is a biopharmaceutical company specializing in botulinum toxin-based pharmaceuticals for aesthetic and therapeutic applications. The company operates two marketed products: Re N Tox Inj (domestic use, 100 units) and Re N Tox (export use, 100 and 200 units), both containing Clostridium botulinum toxin Type A for temporary improvement of moderate to severe glabellar lines. The product portfolio is supported by a pipeline of next-generation botulinum toxin formulations (BCD200 in Phase 3, PRB004/002/005 in earlier stages) and broader biotech C&D (Connect & Development) initiatives including dermal fillers. The company operates GMP-certified manufacturing facilities in Gangneung, South Korea, and is expanding production capacity with a second plant (EU-GMP standard) targeting 6 million vials per year by 2026.

Differentiator

Problem solved

Functional benefit

Brands

• Re N Tox®주 (내수용): Botulinum toxin product for domestic use, 100 units, indicated for temporary improvement of moderate to severe glabellar lines.
• Re N Tox™ (수출용)

Products and services

• Re N Tox Inj (리엔톡주) – Domestic Use Prescription Clostridium botulinum toxin Type A injectable (100 units) for the domestic Korean market, indicated for temporary improvement of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adults aged 19–65. Distributed as a sealed vial, stored refrigerated at 2–8°C, with a 36-month shelf life; sold through prescription-based channels to Korean medical institutions.
• Re N Tox (리엔톡스주) – Export Use Prescription Clostridium botulinum toxin Type A injectable for international export markets, available in 100-unit and 200-unit formulations. Indicated for temporary improvement of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adults aged 19–65; sold through prescription-based export channels to medical institutions in approved territories.

Quantifiable outcome

• 99.97% purity achieved in botulinum toxin protein purification
• +3 more outcomes

Named customers3 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered minor and core.

• Yojin Construction Industry (요진건설산업)minorOthers · 22 September 2023Construction partnership for building the second factory facility. Yojin Construction Industry was contracted to construct the 7,905㎡ manufacturing facility at Gangneung Science Industrial Complex, scheduled for completion in 2026.
• Gangneung City and Gangwon Province (강릉시·강원도)coreStrategic or Co-development Partner · 8 June 2023Investment agreement for factory expansion. Gangneung City and Gangwon Province partnered with PharmaResearch Bio for the Gangneung factory expansion project, providing administrative support and investment incentives for the 193 billion KRW project.

Scale indicators6 records

Recent moves12 records

Expansion highlights5 records

Broad incumbents

• AbbVie (Allergan Aesthetics): AbbVie acquired Allergan in 2020 and markets Botox, the dominant global botulinum toxin brand. While a massive diversified pharma, Botox remains the gold-standard neurotoxin against which all competitors including PharmaResearch Bio's Re N Tox are benchmarked in aesthetic and therapeutic indications.
• Ipsen: French pharmaceutical company that markets Dysport (abobotulinumtoxinA), one of the leading botulinum toxin brands globally. Competes directly with PharmaResearch Bio in aesthetic and therapeutic neurotoxin indications with established distribution networks across Europe and other markets.
• Merz Aesthetics: Merz markets Xeomin/Bocouture (incobotulinumtoxinA), a major botulinum toxin competitor. As a broader aesthetics player with portfolio spanning fillers and toxins, it competes with PharmaResearch Bio in the aesthetic neurotoxin market with similar clinic-channel GTM approach.
• Galderma: Global aesthetics-focused company (spun out from Nestlé) with portfolio including Restylane fillers and other aesthetic products. Broader incumbent in aesthetics, partnering with Ipsen on Azzalure distribution in some markets, and competing with PharmaResearch Bio's expanding portfolio of toxin and filler products.

Direct peers

• Hugel: Korean botulinum toxin manufacturer marketing Botulax/Letybo - the most directly comparable Korean competitor to PharmaResearch Bio. Hugel has established global export presence and competes head-to-head in similar Asian and international markets with comparable go-to-market and regulatory strategies.
• Daewoong Pharmaceutical: Korean pharmaceutical company marketing Nabota (prabotulinumtoxinA), a directly competitive botulinum toxin. Like PharmaResearch Bio, Daewoong has pursued international approvals and competes in both domestic Korean and global neurotoxin markets with similar product positioning.
• Medytox: Korean botulinum toxin manufacturer known for Meditoxin/A型 products. A direct competitor in the Korean and Asian botulinum toxin markets, operating in the same product category and targeting similar medical aesthetic and therapeutic use cases as PharmaResearch Bio.
• Evolus: US-based aesthetic pharmaceutical company focused on neurotoxins, marketing Jeuveau (prabotulinumtoxinA-xvfs). Pure-play aesthetic neurotoxin competitor with highly comparable go-to-market focus on medical aesthetic clinics and dermatology practices - very similar business model to PharmaResearch Bio's clinic-channel approach.

Emerging players

• Revance Therapeutics: US company that launched Daxxify (daxibotulinumtoxinA-lanm), a next-generation botulinum toxin with longer duration claims. Represents emerging competitive technology that could disrupt the standard botulinum toxin market where PharmaResearch Bio competes, especially if longer-duration claims drive share shifts.

Regional players

• Croma-Pharma: Austrian aesthetic pharmaceutical company distributing Azzalure botulinum toxin in partnership with Ipsen across European markets. Provides a comparable European-focused specialty distribution model relevant to PharmaResearch Bio's planned EU-GMP expansion and serves as a regional specialist benchmark.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pharma Research Bio